NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix

[1]  S. Giordano,et al.  The Dual Roles of NRF2 in Cancer. , 2016, Trends in molecular medicine.

[2]  Lijuan Lin,et al.  NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix , 2014, BMC Cancer.

[3]  Lijuan Lin,et al.  Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. , 2014, Experimental and molecular pathology.

[4]  Lijuan Lin,et al.  Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. , 2014, Experimental and molecular pathology.

[5]  K. Houali,et al.  Human Papillomavirus and Epstein-Barr virus co-infection in Cervical Carcinoma in Algerian women , 2013, Virology Journal.

[6]  Yulin Li,et al.  High expression of ezrin predicts poor prognosis in uterine cervical cancer , 2013, BMC Cancer.

[7]  Ç. Şakalar,et al.  Pronounced transcriptional regulation of apoptotic and TNF–NF-kappa-B signaling genes during the course of thymoquinone mediated apoptosis in HeLa cells , 2013, Molecular and Cellular Biochemistry.

[8]  G. Jin,et al.  DEK over expression as an independent biomarker for poor prognosis in colorectal cancer , 2013, BMC Cancer.

[9]  P. Auvinen,et al.  Identification and Validation of Human Papillomavirus Encoded microRNAs , 2013, PloS one.

[10]  M. H. Lee,et al.  NAD(P)H: Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Polymorphisms in Papillary Thyroid Microcarcinoma: Correlation with Phenotype , 2013, Yonsei medical journal.

[11]  A. Alachkar,et al.  The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis , 2013, British Journal of Cancer.

[12]  Min Jeong Kim,et al.  Anthocyanins from Vitis coignetiae Pulliat Inhibit Cancer Invasion and Epithelial-Mesenchymal Transition, but These Effects Can Be Attenuated by Tumor Necrosis Factor in Human Uterine Cervical Cancer HeLa Cells , 2013, Evidence-based complementary and alternative medicine : eCAM.

[13]  S. Kudoh,et al.  C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin , 2013 .

[14]  N. Behtash,et al.  Risk Factors and Clinical Aspects of Recurrent Invasive Cervical Carcinoma , 2012, The Journal of Obstetrics and Gynecology of India.

[15]  B. Mittal,et al.  Role of NQO1 609C>T and NQO2 −3423G>A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis , 2012, Molecular Biology Reports.

[16]  A. Puapairoj,et al.  NQO1 expression correlates with cholangiocarcinoma prognosis. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[17]  H. Üstün,et al.  ABO blood group and risk of pancreatic cancer in a Turkish population in Western Blacksea region. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[18]  D. Greco,et al.  Human Papillomavirus 16 E5 Modulates the Expression of Host MicroRNAs , 2011, PloS one.

[19]  Gang Li,et al.  The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. , 2010, Free radical biology & medicine.

[20]  U. Kukongviriyapan,et al.  Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. , 2010, World journal of gastroenterology.

[21]  I. Borecki,et al.  TP53, MDM2, NQO1, and Susceptibility to Cervical Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[22]  P. Souček,et al.  Polymorphisms in metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe. , 2010, Neoplasma.

[23]  Benjamin Geiger,et al.  Anomalous Features of EMT during Keratinocyte Transformation , 2008, PloS one.

[24]  K. Shroyer,et al.  NQO1 Expression in Pancreatic Cancer and Its Potential Use as a Biomarker , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[25]  K. Charoenkwan,et al.  Limited value of vaginal cytology in detecting recurrent disease after radical hysterectomy for early stage cervical carcinoma. , 2006, Asian Pacific journal of cancer prevention : APJCP.

[26]  A. Kong,et al.  Pharmacogenomics of Phenolic Antioxidant Butylated Hydroxyanisole (BHA) in the Small Intestine and Liver of Nrf2 Knockout and C57BL/6J Mice , 2006, Pharmaceutical Research.

[27]  V. Vasiliou,et al.  Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family , 2006, Human Genomics.

[28]  R. Walker,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .

[29]  A. Dinkova-Kostova,et al.  Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. , 2004, Methods in enzymology.

[30]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[31]  Yiannis Koutalos,et al.  Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. , 2002, Cancer research.

[32]  D. Ross,et al.  Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. , 2000, Free radical biology & medicine.

[33]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[34]  A. Tomida,et al.  Immunological Quantitation of DT‐Diaphorase in Carcinoma Cell Lines and Clinical Colon Cancers: Advanced Tumors Express Greater Levels of DT‐Diaphorase , 1998, Japanese journal of cancer research : Gann.

[35]  D. Ross,et al.  Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  T. Ebert,et al.  Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. , 1997, Pharmacogenetics.

[37]  P. O'dwyer,et al.  Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. , 1997, Molecular pharmacology.

[38]  K. Buetow,et al.  Re: Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. , 1995, Journal of the National Cancer Institute.

[39]  J. Kolesar,et al.  Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. , 1995, Journal of the National Cancer Institute.

[40]  P. O'dwyer,et al.  Involvement of NF-κB in the induction of NAD(P)H: Quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C , 1995 .

[41]  P. O'dwyer,et al.  Involvement of NF-kappa B in the induction of NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C. , 1995, Biochemical pharmacology.

[42]  S. De Flora,et al.  Cytosolic activation of aromatic and heterocyclic amines. Inhibition by dicoumarol and enhancement in viral hepatitis B. , 1994, Environmental health perspectives.